250 related articles for article (PubMed ID: 30547192)
1. Increase in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): a possible drug interaction?
Abu-Amna M; Bar-Sela G
Cancer Chemother Pharmacol; 2019 Mar; 83(3):545-550. PubMed ID: 30547192
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors not associated with hypomagnesemia, regardless of dose or concomitant diuretic use.
Chowdhry M; Shah K; Kemper S; Zekan D; Carter W; McJunkin B
J Gastroenterol Hepatol; 2018 Oct; 33(10):1717-1721. PubMed ID: 29514412
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and risk factors of long-term proton pump inhibitors-associated hypomagnesemia: a cross-sectional study in hospitalized patients.
Recart DA; Ferraris A; Petriglieri CI; Alonso Serena M; Bonella MB; Posadas-Martinez ML
Intern Emerg Med; 2021 Apr; 16(3):711-717. PubMed ID: 33001349
[TBL] [Abstract][Full Text] [Related]
4. Risk Evaluation of Proton Pump Inhibitors for Panitumumab-Related Hypomagnesemia in Patients with Metastatic Colorectal Cancer.
Katsura H; Suga Y; Kubo A; Sugimura H; Kumatani K; Haruki K; Yonezawa M; Narita A; Ishijima R; Ikesue H; Toi H; Takata N
Biol Pharm Bull; 2024; 47(1):98-103. PubMed ID: 38171783
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us?
Luk CP; Parsons R; Lee YP; Hughes JD
Ann Pharmacother; 2013 Jun; 47(6):773-80. PubMed ID: 23632281
[TBL] [Abstract][Full Text] [Related]
6. Common single nucleotide polymorphisms in transient receptor potential melastatin type 6 increase the risk for proton pump inhibitor-induced hypomagnesemia: a case-control study.
Hess MW; de Baaij JH; Broekman MM; Bisseling TM; Haarhuis BJ; Tan AC; Te Morsche RH; Hoenderop JG; Bindels RJ; Drenth JP
Pharmacogenet Genomics; 2017 Mar; 27(3):83-88. PubMed ID: 27926584
[TBL] [Abstract][Full Text] [Related]
7. Acne during adolescence did not predict skin rash reaction to cetuximab.
Bar-Sela G; Avgush S; Kaidar-Person O; Beny A; Semenisty V; Liel Y; Bergman R; Khamaysi Z
Anticancer Drugs; 2016 Nov; 27(10):1033-7. PubMed ID: 27509079
[TBL] [Abstract][Full Text] [Related]
8. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.
Kieboom BC; Kiefte-de Jong JC; Eijgelsheim M; Franco OH; Kuipers EJ; Hofman A; Zietse R; Stricker BH; Hoorn EJ
Am J Kidney Dis; 2015 Nov; 66(5):775-82. PubMed ID: 26123862
[TBL] [Abstract][Full Text] [Related]
10. Low Prevalence of Hypomagnesemia in Long-term Recipients of Proton Pump Inhibitors in a Managed Care Cohort.
Sharara AI; Chalhoub JM; Hammoud N; Harb AH; Sarkis FS; Hamadeh G
Clin Gastroenterol Hepatol; 2016 Feb; 14(2):317-21. PubMed ID: 26499924
[TBL] [Abstract][Full Text] [Related]
11. Hypomagnesemia and proton-pump inhibitors.
Famularo G; Gasbarrone L; Minisola G
Expert Opin Drug Saf; 2013 Sep; 12(5):709-16. PubMed ID: 23808631
[TBL] [Abstract][Full Text] [Related]
12. The Prevalence of Hypomagnesemia in Hospitalized Type 2 Diabetic Patients Treated with Diuretics and/or Proton Pump Inhibitors.
Mengesha B; Levi D; Kroonenberg M; Koren R; Golik A; Koren S
Isr Med Assoc J; 2021 Apr; 23(4):245-250. PubMed ID: 33899358
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors and hypomagnesemia: a rare but serious complication.
Perazella MA
Kidney Int; 2013 Apr; 83(4):553-6. PubMed ID: 23538697
[TBL] [Abstract][Full Text] [Related]
14. The association of proton pump inhibitors and hypomagnesemia in the community setting.
Markovits N; Loebstein R; Halkin H; Bialik M; Landes-Westerman J; Lomnicky J; Kurnik D
J Clin Pharmacol; 2014 Aug; 54(8):889-95. PubMed ID: 24771616
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab-induced hypomagnesemia in patients with colorectal cancer.
Fakih MG; Wilding G; Lombardo J
Clin Colorectal Cancer; 2006 Jul; 6(2):152-6. PubMed ID: 16945172
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
[TBL] [Abstract][Full Text] [Related]
17. Is there a relationship between hypomagnesemia and proton-pump inhibitors in patients on chronic hemodialysis?
Mikolasevic I; Milic S; Stimac D; Zaputovic L; Lukenda Zanko V; Gulin T; Jakopcic I; Klaric D; Gulin M; Orlic L
Eur J Intern Med; 2016 May; 30():99-103. PubMed ID: 26905320
[TBL] [Abstract][Full Text] [Related]
18. Uses of proton pump inhibitors and hypomagnesemia.
Gau JT; Yang YX; Chen R; Kao TC
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):553-9. PubMed ID: 22337212
[TBL] [Abstract][Full Text] [Related]
19. Does the use of proton pump inhibitors increase the risk of hypomagnesemia: An updated systematic review and meta-analysis.
Liao S; Gan L; Mei Z
Medicine (Baltimore); 2019 Mar; 98(13):e15011. PubMed ID: 30921222
[TBL] [Abstract][Full Text] [Related]
20. Hypomagnesemia Among Outpatient Long-Term Proton Pump Inhibitor Users.
Biyik M; Solak Y; Ucar R; Cifci S; Tekis D; Polat İ; Göktepe MH; Sakiz D; Ataseven H; Demir A
Am J Ther; 2017; 24(1):e52-e55. PubMed ID: 25353358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
